Compare TPR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPR | MRNA |
|---|---|---|
| Founded | 1941 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.4B | 26.7B |
| IPO Year | 2000 | 2018 |
| Metric | TPR | MRNA |
|---|---|---|
| Price | $144.24 | $79.08 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 12 |
| Target Price | ★ $145.44 | $34.27 |
| AVG Volume (30 Days) | 2.6M | ★ 8.0M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 5.58 | N/A |
| Revenue | $5,880,000,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $12.39 | $9.36 |
| Revenue Next Year | $5.36 | $15.43 |
| P/E Ratio | $25.84 | ★ N/A |
| Revenue Growth | ★ 31.01 | 4.29 |
| 52 Week Low | $90.35 | $22.28 |
| 52 Week High | $161.97 | $81.40 |
| Indicator | TPR | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 49.30 | 79.87 |
| Support Level | $136.82 | $45.69 |
| Resistance Level | $148.25 | N/A |
| Average True Range (ATR) | 5.41 | 5.44 |
| MACD | -0.50 | 2.10 |
| Stochastic Oscillator | 9.73 | 95.25 |
Based in New York City, Tapestry is the parent company of accessories and fashion brand Coach, which accounted for 80% of its revenue and well over 90% of its operating profit in fiscal 2025. Handbags accounted for 58% of the brand's fiscal 2025 revenue. Coach products are sold through more than 900 company-owned stores, e-commerce, and third-party stores in North America, Asia, and Europe. Tapestry also owns Kate Spade (17% of fiscal 2025 revenue), which operates about 170 stores and generated 52% of its sales from handbags in fiscal 2025. Kate Spade is known for its colorful patterns and graphics. Tapestry sold its smallest brand, luxury footwear maker Stuart Weitzman, to Caleres in August 2025.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.